stars 1 stars 2 stars 3

For the last two decades, electrical neurostimulation has been an established therapy widely used as a last resort for patients with various neurological and psychiatric illnesses. Typically in cases where pharmacological options have been exhausted and where neurostimulation offers a more reversible option compared for example to surgical lesioning of the brain. Today this technology is used in Deep Brain Stimulation (DBS), Spinal Cord Stimulation (SCS) and Vagal Nerve Stimulation (VNS), however, all have limitations that prevent a broader usage. Existing technologies are highly invasive, requires implanted batteries and are so far depending on physician intervention to adjust and ensure optimal treatment. Cenexum’s solution combines key features for safe and effective treatment and patient convenience. These are: - Intelligent and stand-alone miniatured implantable device enabling bio-inspired data processing and stimulation in a closed loop - Wireless communication via mild electrical impulses between microscale-implant device and external unit - Wirelessly powered implantable device enabling long lasting solution for the patient without need for implanted battery - Less complexity for neurosurgeons and the patient - Suitable for implantation at the core location of the disease to treat

Cenexum Questions

Dennis Henriksen is the CEO of Cenexum.

1 people are employed at Cenexum.

Top Cenexum Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users